The present invention provides an arsenite oxidase enzyme modified to prevent translocation by modification of a translocation signal sequence. A microorganism modified to express the heterologous arsenite oxidase enzyme is also provided by the invention, together with a device for detecting the presence of arsenite in a sample.

The present invention relates to methods for the diagnosis and the treatment of cancer, in particular breast cancer. In particular, the present invention relates to a method of diagnosing cancer in a subject comprising the steps of i) determining the expression level of 11βHSD1 and/or 11βHSD2 in a sample obtained from the subject, ii) comparing the expression level determined at step i) with its predetermined reference value and ii) concluding that the subject suffers from a cancer when the expression level of 11βHSD1 is lower than its predetermined reference value or when the expression level of 11βHSD2 is higher than its predetermined reference value.

Provided herein are methods for diagnosing a psychotic disorder, such as schizophrenia, schizoaffective disorder or psychosis, predicated on a determination of a methylation phenotype of the subject based in part on the identity of a specific polymorphism in the MTHFR gene and the analysis of a suite of biomarkers and other functional measures and indices. Also provided herein are methods for predicting prognosis and functional outcomes for subjects having a psychotic disorder, and for treating subjects having a psychotic disorder.

The disclosed technology relates to chemical entities for the detection of wounds, e.g., chronic wounds or infected wounds, including compositions, substrates, kits, dressing materials, and articles, and systems containing such compounds. The disclosed technology further relates to methods of using these compositions, kits and systems in diagnostic assays, and in the diagnosis and/or detection of chronic or infected wounds based on enzymatic action on specific moieties and/or reaction sites. The disclosed technology additionally relates to detection of pathogenic, e.g., bacterial and/or viral substances, such as enzymes and substrates, at the wound situs. Additional disclosure relates to methods of characterizing wounds based on expression of a plurality of markers and using such information to treat, manage, and follow-up patients suffering from chronic or infected wounds.

Methods for treatment and diagnosis of pervasive developmental disorders in humans are described.

The invention relates to a combination of biomarkers and their use in brain injury or mild traumatic brain injury (mTBI) detection. The invention also relates to methods of treating the individual diagnosed with a traumatic brain injury (TBI) or a mild traumatic brain injury (mTBI) using such biomarkers.

Methods of diagnosing infections are disclosed. In one embodiment, the method comprises measuring the amount of each of the polypeptides TRAIL, CRP, IP10 and at least one additional polypeptide selected from the group consisting of IL-6 and PCT.

The present disclosure provides a method of determining treatment for cancer comprising identifying the absence of malic enzyme 1 (ME1) and treating with an inducer of ferroptosis.

The present invention relates to a method of detecting the presence of an antibody to an avian influenza hemagglutinin antigen in a sample from a subject, wherein the antibody binds to an epitope of an avian influenza hemagglutinin antigen, comprising the steps of cloning a nucleic acid encoding an avian influenza antigen into a vector, infiltrating a plant cell with the vector, recovering the antigen from the plant, contacting the sample with the antigen, and detecting the formation of an antibody-antigen complex, wherein the antibody-antigen complex comprises antibodies in the sample bound to the antigen and wherein the formation of an antibody-antigen complex confirms that the subject has been exposed to an avian influenza hemagglutinin antigen. The present invention also relates to a device for assaying the presence of an antibody to avian influenza hemagglutinin antigen in a sample from a subject.

Disclosed are compositions and methods for inactivating one or more enzymes in a biological sample.